• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Mylan proposes to acquire Perrigo for $205 per share

Mylan proposes to acquire Perrigo for $205 per share

April 9, 2015
CenterWatch Staff

Mylan, a global generics and specialty pharmaceutical company, has made a proposal to acquire Perrigo, an Irish international manufacturer of over-the-counter pharmaceuticals, in a cash-and-stock transaction.

Perrigo shareholders would receive $205 in a combination of cash and Mylan stock for each Perrigo share, which represents more than a 25% premium to Perrigo’s closing price on Friday, April 3 (the last trading date prior to Mylan's proposal), more than a 29% premium to Perrigo's 60-day average share price and more than a 28% premium to Perrigo's 90-day average share price.

Robert J. Coury, executive chairman, Mylan, issued a letter on April 6 to Joseph C. Papa, president, CEO and chairman of Perrigo, proposing the acquisition.

Coury wrote, “As you and I have discussed on a number of occasions over the past few years, a combination of Mylan and Perrigo offers clear and compelling strategic and financial benefits, has sound industrial logic and would create a global leader with a unique and one-of-a-kind profile. We have complementary operations across all of our businesses, both from a product and geographic perspective. In an environment where scale and reach are becoming increasingly important, the combination of our companies would result in an unmatched global platform, substantial revenue and operating synergies and enhanced long-term growth potential, all of which would serve to create significant value for the combined company's shareholders and other stakeholders.”

The combined company would have a strong financial profile including:

  • Approximately $15.3 billion in 2014 pro forma sales
  • Substantial free cash flows driving rapid deleveraging and enhanced reinvestment into the business
  • Synergies resulting in operating margin expansion and EPS accretion
  • A rich pipeline of launches
  • A stronger, larger and more diverse platform to create enhanced and more predictable earnings growth
  • Greater opportunities for continued growth through strategic acquisitions.

Coury proposed Papa join as co-chairman with Coury and as a member of the Mylan board. Coury wrote, “In addition, I look forward to discussing with you the possibility of potentially including other Perrigo directors on the Mylan board.”

“The Mylan board believes that continuity of our management team is critical to the success of the combined company,” wrote Coury, “As such, I will continue to serve as Mylan's executive chairman, Heather Bresch will continue to serve as CEO and Rajiv Malik will continue to serve as president.”

The proposal is subject to the pre-condition of confirmatory due diligence, which may be waived by Mylan at its discretion. This announcement is not an announcement of a firm intention to make an offer under rule 2.5 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, and there can be no certainty that an offer will be made, even if the due diligence pre-condition is satisfied or waived.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing